^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MB-101

    i
    Associations
    News

    Trials

    Company:
    Fortress
    Drug class:
    IL-13-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (NCI-2014-01488) (NCT02208362)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/18/2015
    Primary completion :
    02/08/2021
    Completion :
    07/08/2025
    IL13RA2
    |
    CD123 expression
    |
    MB-101